ABT-737 50 mg | 99.30%
TargetMol
ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w (EC50s: 78.7/30.3/197.8 nM).
More Information Supplier PageABT-737
Search Results
ABT-737 25 mg | 99.30%
TargetMol
ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w (EC50s: 78.7/30.3/197.8 nM).
More Information Supplier PageABT-737
FH1 50 mg | 99.95%
TargetMol
FH1 (BRD-K4477), a small molecule, enhances the functions of hepatocytes and promotes differentiation hepatocytes derived by iPS.
More Information Supplier PageFH1
PHA-793887 10 mg | 100.00%
TargetMol
PHA-793887 has been used in trials studying the treatment of Advanced/Metastatic Solid Tumors.
More Information Supplier PagePHA-793887
AEE788 5 mg | Purity Not Available
TargetMol
AEE788 has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Brain and Central Nervous System Tumors.
More Information Supplier PageAEE788
AEE788 50 mg | Purity Not Available
TargetMol
AEE788 has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Brain and Central Nervous System Tumors.
More Information Supplier PageAEE788
AEE788 25 mg | Purity Not Available
TargetMol
AEE788 has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Brain and Central Nervous System Tumors.
More Information Supplier PageAEE788
AEE788 10 mg | Purity Not Available
TargetMol
AEE788 has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Brain and Central Nervous System Tumors.
More Information Supplier PageAEE788
PHA-793887 5 mg | 100.00%
TargetMol
PHA-793887 has been used in trials studying the treatment of Advanced/Metastatic Solid Tumors.
More Information Supplier PagePHA-793887
PHA-793887 50 mg | 100.00%
TargetMol
PHA-793887 has been used in trials studying the treatment of Advanced/Metastatic Solid Tumors.
More Information Supplier PagePHA-793887